John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 9,900 shares at $157.55 ($1.6M) on 2021-11-16, disclosed to the SEC on 2021-11-18.
Open-market sale of $1.6M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $157.55 | 800 | $126K | 8.0% |
| 2 | $157.55 | 800 | $126K | 8.0% |
| 3 | $158.79 | 3,052 | $485K | 30.8% |
| 4 | $158.79 | 3,052 | $485K | 30.8% |
| 5 | $159.80 | 1,048 | $167K | 10.7% |
| 6 | $159.80 | 1,048 |
| $167K |
| 10.7% |
| 7 | $160.32 | 100 | $16K | 1.0% |
| Total | $158.82 avg | 9,900 | $1.6M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |